In short
Clinical trials of UNFRACTIONATED HEPARIN, PORCINE, CONJUGATED WITH HUMAN SERUM ALBUMIN are studying antithrombotic treatment in people with severe poor blood flow in the limbs. The research is focused on safety, tolerability, and bleeding outcomes in patients with peripheral arterial occlusive disease and chronic limb-threatening ischemia.
Key points
- Clinical trials of UNFRACTIONATED HEPARIN, PORCINE, CONJUGATED WITH HUMAN SERUM ALBUMIN are focused on severe limb blood flow problems, especially peripheral arterial occlusive disease and chronic limb-threatening ischemia. The study is in Phase 2 and is authorised. It includes patients undergoing endovascular revascularization, which is a procedure to improve blood flow inside the vessels. The main goals are to check safety and tolerability, with close attention to treatment-emergent adverse events and bleeding. The planned enrollment is 42 participants. The trial also records physical exams, vital signs, laboratory data, and surgical complications.
Trial overview
This clinical research is about antithrombotic treatment, which means treatment aimed at preventing blood clots. The study title says it is an APAC antithrombotic treatment study for limb-threatening impairment of blood flow, also called the HEALING-study.
The trial compares APAC with sodium chloride and with Heparin LEO 5000 IU/ml injektioneste, liuos, all given by intravenous use in the study plan. The source data do not give more detail about the substance UNFRACTIONATED HEPARIN, PORCINE, CONJUGATED WITH HUMAN SERUM ALBUMIN itself, so this article focuses only on the trial information provided.
Who is being studied
The trial targets people with peripheral arterial occlusive disease (PAOD) and chronic limb-threatening ischemia (CLTI). PAOD means the arteries in the arms or legs are narrowed or blocked, while CLTI means a severe form of poor blood flow that can threaten the limb.
The brief summary also says the study is in patients undergoing endovascular revascularization, which is a procedure done inside the blood vessels to improve blood flow. This tells us the study population is not general healthy volunteers, but patients with serious circulation problems who need a vessel procedure.
Study design and phase
This is an interventional study, meaning the researchers give a treatment and then observe what happens. It is listed as Phase 2, which usually means the study is looking more closely at safety and early signs of benefit in a smaller group of patients.
The brief summary divides the work into Part A and Part B. Part A is designed to evaluate the safety and tolerability of intravenous APAC for a single infusion and weekly dosing, while Part B is meant to establish the safety of selected doses and dosing frequency for periprocedural intra-arterial and weekly intravenous APAC in patients having endovascular revascularization.
What the trial measures
The main endpoint is the occurrence and severity of treatment-emergent adverse events (TEAEs), which are health problems that appear or become worse after treatment starts. In Part A, TEAEs are measured from baseline to Day 29 and Day 90 after the first dose of APAC, depending on the part of the study.
The study also records physical examination findings, vital signs, clinical laboratory data, and bleeding events measured with the ISTH bleeding score, a standard way to describe bleeding in clinical research. In Part B, the trial also tracks surgical adverse events using the Clavien-Dindo classification, which is a system for grading how serious surgical complications are.
These outcomes show that the study is mainly focused on safety, tolerability, and bleeding risk rather than on long-term effectiveness outcomes.
Trial status and size
The trial status is Authorised. The planned enrollment is 42 participants, which means the study is relatively small.
Small Phase 2 studies like this are often used to gather early information before larger studies are done. In this case, the source data show a focused safety study in a specific high-risk patient group.
Patient-focused summary
For patients, the key point is that this research is looking at people with serious limb blood flow problems who may need a vessel-opening procedure. The study is testing how safe and tolerable the treatment plan is, and it watches closely for bleeding and other side effects. The trial does not describe cure outcomes in the source data; instead, it mainly checks whether the treatment can be given safely in this setting.